{
    "organizations": [],
    "uuid": "8d169efbe60be726239c22182c1278a216ffa6f5",
    "author": "cnbc.com",
    "url": "http://www.cnbc.com/2018/02/21/globe-newswire-evoke-pharma-schedules-conference-call-and-webcast-for-fourth-quarter-and-full-year-2017-financial-results.html",
    "ord_in_thread": 0,
    "title": "Evoke Pharma Schedules Conference Call and Webcast for Fourth Quarter and Full-Year 2017 Financial Results",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "SOLANA BEACH, Calif., Feb. 21, 2018 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal diseases, announced today that the Company will release financial results for the fourth quarter and full year ended December 31, 2017 on Wednesday, March 7, 2018, after the market closes.\nEvoke will hold a conference call on Wednesday, March 7, 2018 at 4:30 pm ET to discuss the results. Participants should dial 1-877-407-0789 (United States) or 1-201-689-8562 (International) and mention Evoke Pharma. A live webcast of the conference call will also be available on the investor relations page of the Company's corporate website at www.evokepharma.com .\nAfter the live webcast, the event will be archived on Evoke's website for one year. In addition, a telephonic replay of the call will be available until March 14, 2018. The replay can be accessed by dialing 1-844-512-2921 (United States) or 1-412-317-6671 (International) with confirmation code 13676791.\nAbout Evoke Pharma, Inc.\nEvoke is a specialty pharmaceutical company focused primarily on the development of drugs to treat GI disorders and diseases. The Company is developing Gimoti, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent gastroparesis in women with diabetes mellitus. Diabetic gastroparesis is a GI disorder afflicting millions of sufferers worldwide, in which the stomach takes too long to empty its contents resulting in serious digestive system symptoms. Metoclopramide is the only product currently approved in the United States to treat gastroparesis, and is currently available only in oral and intravenous forms. Gimoti is a novel formulation of this drug, designed to provide systemic delivery of metoclopramide through nasal administration. Visit www.EvokePharma.com for more information.\nInvestor Contact:\nThe Ruth Group\nTram Bui\nTel: 646-536-7035\ntbui@theruthgroup.com\nSource:Evoke Pharma, Inc.",
    "published": "2018-02-21T16:30:00.000+02:00",
    "crawled": "2018-02-21T18:22:52.014+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "solana",
        "beach",
        "globe",
        "newswire",
        "evoke",
        "pharma",
        "nasdaq",
        "evok",
        "specialty",
        "pharmaceutical",
        "company",
        "focused",
        "treatment",
        "gastrointestinal",
        "disease",
        "announced",
        "today",
        "company",
        "release",
        "financial",
        "result",
        "fourth",
        "quarter",
        "full",
        "year",
        "ended",
        "december",
        "wednesday",
        "march",
        "market",
        "close",
        "evoke",
        "hold",
        "conference",
        "call",
        "wednesday",
        "march",
        "pm",
        "et",
        "discus",
        "result",
        "participant",
        "dial",
        "united",
        "state",
        "international",
        "mention",
        "evoke",
        "pharma",
        "live",
        "webcast",
        "conference",
        "call",
        "also",
        "available",
        "investor",
        "relation",
        "page",
        "company",
        "corporate",
        "website",
        "live",
        "webcast",
        "event",
        "archived",
        "evoke",
        "website",
        "one",
        "year",
        "addition",
        "telephonic",
        "replay",
        "call",
        "available",
        "march",
        "replay",
        "accessed",
        "dialing",
        "united",
        "state",
        "international",
        "confirmation",
        "code",
        "evoke",
        "pharma",
        "evoke",
        "specialty",
        "pharmaceutical",
        "company",
        "focused",
        "primarily",
        "development",
        "drug",
        "treat",
        "gi",
        "disorder",
        "disease",
        "company",
        "developing",
        "gimoti",
        "metoclopramide",
        "nasal",
        "spray",
        "relief",
        "symptom",
        "associated",
        "acute",
        "recurrent",
        "gastroparesis",
        "woman",
        "diabetes",
        "mellitus",
        "diabetic",
        "gastroparesis",
        "gi",
        "disorder",
        "afflicting",
        "million",
        "sufferer",
        "worldwide",
        "stomach",
        "take",
        "long",
        "empty",
        "content",
        "resulting",
        "serious",
        "digestive",
        "system",
        "symptom",
        "metoclopramide",
        "product",
        "currently",
        "approved",
        "united",
        "state",
        "treat",
        "gastroparesis",
        "currently",
        "available",
        "oral",
        "intravenous",
        "form",
        "gimoti",
        "novel",
        "formulation",
        "drug",
        "designed",
        "provide",
        "systemic",
        "delivery",
        "metoclopramide",
        "nasal",
        "administration",
        "visit",
        "information",
        "investor",
        "contact",
        "ruth",
        "group",
        "tram",
        "bui",
        "tel",
        "tbui",
        "source",
        "evoke",
        "pharma",
        "inc"
    ]
}